In 596 patients with RA managed over a decade in a community practice setting, 879 slow acting antirheumatic drug (SAARD) treatment episodes were analyzed using 5-year life tables. The probability of termination of therapy reached 50% by 9-24 months for all drugs except for methotrexate (MTX), which had reached only 62% by 5 years. MTX treatments were of significantly longer duration than those of all other SAARD (p < 0.001); terminations for both inefficacy (p < 0.001) and toxicity (NS) were less likely. These findings concur with recent evidence suggesting that MTX is a superior SAARD in this setting.
|Number of pages||5|
|Journal||The Journal of Rheumatology|
|Publication status||Published - 1 Jan 1992|
- antirheumatic drugs
- community practice
- rheumatoid arthritis